ERBB2 and breast carcinoma: The EGFRvIII encoding sequence was introduced into the HER2-positive breast cancer cell lines BT474 and SKBR3, and the established EGFRvIII+HER2+ cells (Figure S1) were less sensitive to trastuzumab than their parental cells in vitro (Figure 1A).